—
The Global Retinal Disease Therapeutics Market is likely to expand at an impressive rate driven by recent government participation towards the prevention and control of retinal diseases. According to a report published by Fortune Business Insights, titled “Retinal Disease Therapeutics: Global Market Analysis, Insights, and Forecast, 2019-2026,” the market is likely to reach US$ 21,318.0 Mn by the end of 2026. The market was valued at US$ 11,044.2 Mn in 2018 and is likely to witness a CAGR of 8.6% in the forecast period.Sample PDF Brochure:
https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/retinal-disease-therapeutics-market-100311
The Global Retinal Disease Therapeutics Market is consolidated in nature, with only a handful of market players accounting for maximum share of the market. With consolidation, it is becoming increasingly difficult for newer market entrants to establish a stronghold or derive immediate success.Therefore the global market is boosted by products and concepts introduced by existing companies.
Some of the Main Key Players Covered in the Report
• Merck
• Novartis
• Allergan
• Roche
• Regeneron Pharmaceuticals, Inc.
• Santen Pharmaceutical
F. Hoffmann-La Roche AG’s ‘Lucentis’ is Gaining Increasing Popularity
The diabetic retinopathy is a severe kind of disorder that has accounted for the majority of cases of blindness in the US. Lucentis was an instant hit among healthcare professionals after it was backed by a series of clinical trials and approvals from the National Institute of Health (NIH).
One such instance of this development is the “Lucentis” therapy, put forward by F. Hoffmann-La Roche AG. Lucentis was introduced with the aim of providing therapeutic advice and development of products for patients suffering from chronic disease. In 2017, the Food and Drug Administration (FDA) approved Lucentis for diabetic retinopathy.
Get Customization:
https://www.fortunebusinessinsights.com/enquiry/customization/retinal-disease-therapeutics-market-100311
Excellent clinical effects of Lucentis have led to a subsequent rise in demand for medicine among patients. The increasing demand has contributed to the growth of the global retinal disease therapeutics market and is likely to favor the market in the forthcoming years.
Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1 Recent industry developmentssuch as mergers & acquisitions
4.2 Regulatory scenario for keycountries
4.3 Prevalence of Key RetinalDiseases, in Major Countries
5. Global RetinalDisease Therapeutics Market Analysis, Insights and Forecast, 2015-2026
5.1. Key Findings / Summary
5.2 Market Analysis, Insights andForecast – By Disease Indication
5.2.1 MacularDegeneration
5.2.2 DiabeticMacular Edema
5.2.3 DiabeticRetinopathy
5.2.4 RetinalVein Occlusion
5.2.5 Others
5.3. Market Analysis, Insightsand Forecast – By End User
5.3.1 HospitalPharmacy
5.3.2 RetailPharmacy
5.3.3 Others
5.4. Market Analysis, Insightsand Forecast – By Region
5.4.1 NorthAmerica
5.4.2 Europe
5.4.3 AsiaPacific
5.4.4 LatinAmerica
5.4.5 MiddleEast & Africa
North America to Emerge Dominant in the Forecast Period
The increasing government investment towards research and development of retinal disease drugs and diagnostic devices is enabling growth in the retinal diseases therapeutics market in North America. North America has emerged dominant in the global retinal disease therapeutics market in recent years. The Retinal Disease Therapeutics Market in North America was valued at US$ 4056.5Mn in 2018 and is likely to increase in the coming years.
Improved health infrastructures, increasing patient pool, and favourable health reimbursement policies are some of the factors that are likely to boost the regional market in the forthcoming years. High prevalence of retinal diseases in Asia Pacific is a major reason, why this region is estimated to rise with the highest CAGR in the forecast period.
Browse Complete Report Details:
https://www.fortunebusinessinsights.com/industry-reports/retinal-disease-therapeutics-market-100311
About Us:
Fortune Business Insights offers expert corporate ANALYSIS and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Info:
Name: Fortune Business Insights
Email: Send Email
Organization: Fortune Business Insights
Address: Fortune Business Insights Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.
Phone: 14242530390
Website: https://www.fortunebusinessinsights.com
Release ID: 88889929
Google
RSS